Revance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($0.88), $0.12 worse than the analyst estimate of ($0.76). Revenue for the quarter came in at $28.4 million versus the consensus estimate of $28.15 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.